NGM Biopharmaceuticals

YTD

ALL

Why Robinhood?

You can watch NGM and buy or sell other stocks, ETFs, and their options commission-free!

About NGM

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel biologic drug candidates. Its programs include NGM707 and pembrolizumab for treating metastatic solid tumors, Aldafermin for primary sclerosing cholangitis, and NGM120 for hyperemesis gravidarum.

CEO

David J. Woodhouse, PhD, MBA

CEODavid J. Woodhouse, PhD, MBA

Employees

—

Employees—

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

2007

Founded2007

Employees

—

Employees—

NGM Key Statistics

Market cap

128.53M

Market cap128.53M

Price-Earnings ratio

-0.89

Price-Earnings ratio-0.89

Dividend yield

—

Dividend yield—

Average volume

536.23K

Average volume536.23K

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$4.69

52 Week high$4.69

52 Week low

$0.6002

52 Week low$0.6002

People also own

Based on the portfolios of people who own NGM. This list is generated using Robinhood data, and it’s not a recommendation.